What Is Epigenetic Reprogramming—and Could It Reverse Aging?

By Dr. Chinta SidharthanReviewed by Lily Ramsey, LLM

What is epigenetic reprogramming?
How do epigenetic changes influence aging?
Key studies in age reversal via reprogramming
Ethical and technical challenges
Commercial implications and longevity startups
Future directions in epigenetic therapy

Aging is the primary risk factor for numerous life-threatening diseases and has long been a central focus of biological research. Epigenetic reprogramming, a process that can modulate cell fate and cellular age, has emerged as a promising frontier in regenerative medicine and longevity science.

Image Credit: Ground Picture/Shutterstock.com

Epigenetic reprogramming refers to the deliberate modification of epigenetic marks that govern gene expression to reset a cell's biological age or identity. Unlike mutations or changes in deoxyribonucleic acid (DNA) sequence, epigenetic modifications are reversible, making them attractive targets for age-related therapeutic interventions.^1,2

In recent years, the potential to reverse aging through such reprogramming has galvanized research in regenerative medicine and longevity science. Central to this progress is the hypothesis that the loss or distortion of epigenetic information at least partly drives cellular aging.^1,2

In this article, we examine the current understanding of the mechanisms underlying epigenetic reprogramming, how it may influence aging, and the extent to which it could enable cellular rejuvenation. We also analyze key studies, ethical and technical challenges, and the growing commercial interest in age reversal therapies.

Can Neuroplasticity Be Hacked? Exploring the Limits

What is epigenetic reprogramming?

Epigenetic reprogramming involves the reset of epigenetic markers, such as DNA methylation and histone modifications, to a more youthful state. The concept gained scientific interest and traction following the Nobel-prize-winning discovery of induced pluripotent stem cells (iPSCs) by Takahashi and Yamanaka, who demonstrated that somatic cells could be reprogrammed into pluripotent cells using four transcription factors, namely Oct4, Sox2, Klf4, and c-Myc, together known as OSKM factors.³

This process not only resets cellular identity but also reverses age-associated epigenetic markers. The key mechanisms involved in reprogramming included:

DNA methylation: The addition of methyl groups to specific DNA sequences containing a linear repeat of cytosine and guanine nucleotides (CpG dinucleotides). DNA methylation is predominantly involved in the silencing of gene expression.¹

Histone modification: Post-translational changes to the histone proteins that help package DNA into chromosomes. These changes include methylation and acetylation, which influence chromatin structure and gene accessibility.¹

Chromatin remodeling: Changes in nucleosome positioning that significantly alter chromatin structure, regulating the accessibility of transcription factors to the DNA.¹

How do epigenetic changes influence aging?

Aging is accompanied by progressive epigenetic drift — a divergence from the original epigenomic configuration of a young cell. This includes aberrant DNA methylation, histone modifications, and chromatin remodeling, which cumulatively lead to dysregulated gene expression, impaired cellular function, and age-related phenotypes and diseases.^4,5

Studies in yeast, mice, and humans indicate that such changes are not merely correlative but play a causal role in aging. For instance, in monozygotic twins, epigenetic profiles become increasingly dissimilar with age despite identical genetic backgrounds.⁵ Similarly, interventions such as calorie restriction that extend lifespan are known to influence epigenetic states.

Scientists have leveraged this knowledge of the predictable accumulation of DNA methylation tags to develop tools like the epigenetic clock — a biological age estimator.⁶

One of the most prominent versions, Horvath's clock, developed by Steve Horvath in 2013, uses these methylation patterns across multiple tissues to calculate a person's biological age with remarkable accuracy.⁷

Key studies in age reversal via reprogramming

Groundbreaking experiments have shown that epigenetic reprogramming can restore youthful characteristics to aged tissues. A pivotal early study from the laboratory headed by Dr. Juan Carlos Izpisua Belmonte, who is currently the director of Altos Lab’s San Diego Institute of Science, further demonstrated that cyclic expression of the Yamanaka factors (OSKM) in a mouse model exhibiting accelerated aging could extend lifespan and ameliorate aging-associated hallmarks without inducing pluripotency.⁸

By intermittently activating OSKM factors, the researchers avoided the risks of tumorigenesis typically associated with continuous reprogramming. The treated mice showed improved muscle regeneration, enhanced pancreatic function, and more youthful epigenetic profiles, suggesting that partial reprogramming may be a viable strategy for systemic age reversal.⁸

Another study in 2020 conducted by a research team from Harvard Medical School demonstrated that expression of the Oct4, Sox2, and Klf4 (OSK factors) in mouse retinal ganglion cells reversed age-associated DNA methylation and improved visual function.

The intervention required the TET (ten-eleven translocation) enzymes TET1 and TET2 DNA demethylases, which suggested the role of active DNA methylation remodeling in rejuvenation.⁶

Similarly, the cyclic expression of OSKM in another mouse model of progeria or accelerated aging improved tissue function and extended lifespan, supporting the feasibility of in vivo partial reprogramming.⁹

Recent advances also include chemically induced reprogramming. Another research team from Harvard Medical School identified six chemical cocktails, consisting of combinations of small molecules such as valproic acid, forskolin, and tranylcypromine, that were capable of reversing transcriptomic aging in human cells without genetic manipulation, marking a significant step toward clinical translation.¹

Your Biological Age vs. Chronological Age: Why It Matters

Ethical and technical challenges

Despite its promise, epigenetic reprogramming faces substantial hurdles. One of the foremost concerns is the oncogenic risk associated with full reprogramming. Maintaining somatic cell identity while inducing rejuvenation is a critical issue.

The overexpression of OSKM factors risks dedifferentiation or partial reversion to a pluripotent state, which may trigger tumorigenesis or disrupt tissue function.⁸

Epigenetic determinism, or the concept that the expression of traits and behaviors is determined by epigenetic mechanisms and not the DNA sequence alone, also raises ethical concerns.

The notion that life experiences can imprint heritable changes challenges concepts of personal autonomy and complicates privacy protections. There are further concerns about equitable access, especially if reprogramming therapies are commercialized before regulatory standards are established.¹⁰

From a technical perspective, challenges include the development of safe and efficient delivery systems for reprogramming factors, particularly in vivo, where viral vectors can pose integration risks and immune reactions.

Non-integrative systems such as messenger ribonucleic acid (mRNA), proteins, and nanoparticles are under exploration but require further optimization for stability and tissue-specific targeting.^9,11

Other technical challenges include the need for reliable biomarkers to monitor reprogramming efficacy in real time and the potential off-target effects of reprogramming cocktails, especially in heterogeneous tissues with varying epigenetic signatures.^1,5,12

Is Cellular Senescence the Real Cause of Aging?

Commercial implications and longevity startups

The biotech sector has rapidly mobilized to explore the potential of epigenetic reprogramming. Companies such as Altos Labs, Rejuvenate Bio, and Life Biosciences are investing heavily in platforms aimed at extending health span and reversing age-related damage through gene therapy, small molecules, and synthetic biology.^11,13

While most interventions remain in preclinical stages, venture capital investment and pharmaceutical partnerships are accelerating development. For instance, Rejuvenate Bio has initiated proof-of-concept studies for OSK-mediated reprogramming in cardiovascular disease models.¹³

Additionally, Altos Labs has invested substantial resources into building research hubs to investigate safe partial reprogramming protocols. However, the regulatory frameworks currently lag behind the pace of innovation, posing a bottleneck to clinical adoption.¹⁰

Future directions in epigenetic therapy

Epigenetic therapy is poised to become a cornerstone of precision medicine. The current trends indicate that advances in single-cell epigenomics, machine learning, and synthetic biology will enable more precise control of the epigenome.

The focus areas of future research include non-integrative delivery systems, such as mRNA, proteins, and nanoparticles, that can avoid genomic alterations and targeted partial reprogramming to specific tissues or organs.¹²

The identification and use of aging biomarkers to personalize interventions, as well as combination therapies that pair epigenetic modulators with anti-inflammatory drugs and senolytics that eliminate cells associated with tissue damage, are other promising areas of epigenetic therapy.

Moreover, ongoing research into small-molecule epigenetic modulators may yield scalable, non-invasive interventions.¹²

However, the road to clinical translation is complex and marked by numerous ethical and technical challenges. Nonetheless, the pace of scientific discovery in the field of epigenetics and the substantial commercial investment indicate that epigenetic therapies may soon enter the therapeutic landscape.

The ability to safely and effectively manipulate the epigenome brings considerable hope to the future of longevity science.

References

1. Yang, J. H., Petty, C. A., Dixon-McDougall, T., Lopez, M. V., Tyshkovskiy, A., Maybury-Lewis, S., Tian, X., … Sinclair, D. A. (2023). Chemically induced reprogramming to reverse cellular aging. Aging, 15(13), 5966–5989. DOI:10.18632/aging.204896
2. Rando, T. A., & Chang, H. Y. (2012). Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock. Cell, 148(1-2), 46–57. DOI:10.1016/j.cell.2012.01.003
3. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676. DOI:10.1016/j.cell.2006.07.024
4. de Lima Camillo, L. P., & Quinlan, R. B. A. (2021). A ride through the epigenetic landscape: aging reversal by reprogramming. GeroScience, 43(2), 463–485. DOI:10.1007/s11357-021-00358-6
5. Chen, D., & Kerr, C. (2019). The Epigenetics of Stem Cell Aging Comes of Age. Trends in cell biology, 29(7), 563–568. DOI:10.1016/j.tcb.2019.03.006
6. Lu, Y., Brommer, B., Tian, X., Krishnan, A., Meer, M., Wang, C., Vera, D. L., Zeng, … Sinclair, D. A. (2020). Reprogramming to recover youthful epigenetic information and restore vision. Nature, 588(7836), 124–129. DOI:10.1038/s41586-020-2975-4
7. Horvath S. (2013). DNA methylation age of human tissues and cell types. Genome biology, 14(10), R115. DOI:10.1186/gb-2013-14-10-r115
8. Ocampo, A., Reddy, P., Martinez-Redondo, P., Platero-Luengo, A., Hatanaka, F., Hishida, T., Li, M., … Izpisua Belmonte, J. C. (2016). In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. Cell, 167(7), 1719–1733.e12. DOI:10.1016/j.cell.2016.11.052
9. Cipriano, A., Moqri, M., Maybury-Lewis, S. Y., Rogers-Hammond, R., de Jong, T. A., Parker, A., Rasouli, S., Schöler, H. R., Sinclair, D. A., & Sebastiano, V. (2024). Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming. Nature aging, 4(2), 275. DOI:10.1038/s43587-023-00562-3
10. Santaló, J., & Berdasco, M. (2022). Ethical implications of epigenetics in the era of personalized medicine. Clinical epigenetics, 14(1), 44. DOI:10.1186/s13148-022-01263-1
11. Paine, P. T., Nguyen, A., & Ocampo, A. (2024). Partial cellular reprogramming: A deep dive into an emerging rejuvenation technology. Aging cell, 23(2), e14039. DOI:10.1111/acel.14039
12. Pereira, B., Correia, F. P., Alves, I. A., Costa, M., Gameiro, M., Martins, A. P., & Saraiva, J. A. (2024). Epigenetic reprogramming as a key to reverse ageing and increase longevity. Ageing research reviews, 95, 102204. DOI:10.1016/j.arr.2024.102204
13. Macip, C. C., Hasan, R., Hoznek, V., Kim, J., Lu, Y. R., Metzger, L. E., 4th, Sethna, S., & Davidsohn, N. (2024). Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice. Cellular reprogramming, 26(1), 24–32. DOI:10.1089/cell.2023.0072